Prime Medicine Plans BLA Submission for PM359 in CGD, Advances Liver Programs to Clinic
PRME has more than doubled off its 52-week low of $1.11.
Summary
Prime Medicine announced its full-year 2025 financial results and provided a business update, including plans to submit a Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD) and progress towards clinical trials for its Wilson Disease and AATD programs.
Key Events · Product Development and Regulatory · PRME
-
PM359 BLA Submission Planned
Prime Medicine announced its intent to submit a Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD), believing existing clinical data may support accelerated approval.
-
Liver Programs Advancing to Clinic
The company is on track to file Investigational New Drug (IND) and/or Clinical Trial Applications (CTA) for its Wilson Disease program in 1H 2026 and its Alpha-1 Antitrypsin Deficiency (AATD) program in mid-2026, with initial clinical data expected in 2027.
-
Full Year 2025 Financial Results
Prime Medicine reported a net loss of $201.1 million for the year ended December 31, 2025, with cash, cash equivalents, and investments totaling $191.4 million.
-
Cash Runway into 2027
The company expects its current cash position to fund operating expenses and capital expenditure requirements into 2027.
Analysis · PRME · Life Sciences
This filing highlights significant progress in Prime Medicine's clinical development and regulatory strategy, particularly the intent to submit a Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD). The company's belief that existing data may support accelerated approval is a strong positive signal, potentially accelerating market access for this transformative therapy. Furthermore, the advancement of two key liver-focused programs (Wilson Disease and AATD) towards IND/CTA submissions in 2026 underscores the continued progression of its Prime Editing platform. While the company reported an increased net loss and reduced cash position for 2025, the projected cash runway into 2027 provides sufficient time to reach critical clinical milestones. Investors should monitor the BLA submission timeline and the upcoming IND/CTA filings for the liver programs, as these events are crucial for the company's long-term value creation.
At the time of this filing, PRME was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $841.2M. The 52-week trading range was $1.11 to $6.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.